MARKETS / NYSE / DGX

NYSE · SERVICES-MEDICAL LABORATORIES · LARGE CAP

Quest Diagnostics Inc. DGX

19 fiscal years on record · USD · FY2025 reported · SEC filings only

7 YEARS OF DIVIDEND GROWTH

Revenue

$11.0B

▲ 11.8% YoY

Net income

$992.0M

▲ 13.9% YoY

Free cash flow

$1.4B

▲ 49.5% YoY

In brief

What this company does

The company provides information and insights based on a menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The patients the company serves annually comprise approximately one-third of the adult population of the United States, and over a three-year period it serves approximately one-half of the adult population of the United States. During 2025, the company generated net revenues of $11.0 billion. The Company is made up of two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic information services based on the results of laboratory testing. The Diagnostic Solutions group includes the risk assessment services business, which offers solutions for insurers, and the healthcare IT businesses, which offer solutions for healthcare providers and payers. Quest Diagnostics was incorporated in Delaware in 1990, and its predecessor companies date back to 1967.

Written from the business description in QUEST DIAGNOSTICS INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 11.0B

Revenue, FY2025 · full 19-year series below

Revenue $B Net income $B

FY2025 · Revenue 11.0 · Net income 1.0

Compound annual growth

Revenue

+3.7%

+3.2%

+3.9%

+2.8%

Net income

+1.6%

−7.1%

+3.4%

+2.2%

EPS, diluted

+3.2%

−3.5%

+6.0%

+5.3%

Dividend / share

+10.9%

+17.3%

+16.2%

Returned to shareholders

−23.1%

+10.8%

+6.8%

−0.4%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +3.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

9 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 14.1% · Net 9.5%

ROE

FY2025 · ROE 14.2%

Gross margin33.2%

Operating margin14.1%

Net margin9.5%

Return on assets6.5%

EBITDAUSD 2.1B

Each USD of equity produced 14 cents of profit this year.

Cash & shareholders

USD 724.0M

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 1.4

Net buybacks $B Dividends $B

FY2025 · Dividends 0.4 · Net buybacks 0.4

Dividends paidUSD 353.0M

Net buybacksUSD 371.0M

Share of profit73.0%

Consecutive raises7 years

USD 353.0M in dividends and USD 371.0M in buybacks — 73% of the year's profit went back to shareholders.

Total assetsUSD 16.2B

EquityUSD 7.2B

CashUSD 420.0M

Gross debtUSD 5.7B

Net debtUSD 5.3B

Current ratio1.04×

Net debt stands at 73% of equity.

The 19-year record

19 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue $B	11.0	9.9	9.3	9.9	10.8	9.4	7.7	7.5	7.4	7.2	7.5	7.4	7.1	7.4	7.4	7.3	7.5	7.2	6.7
Operating income $B	1.6	1.3	1.3	1.4	2.4	2.0	1.2	1.1	1.2	1.3	1.4	1.0	1.5	1.2	1.0	1.3	1.4	1.2	1.1
EBITDA $B	2.1	1.8	1.7	1.9	2.8	2.3	1.6	1.4	1.4	1.5	1.7	1.3	1.8	1.5	1.3	1.5	1.6	1.5	1.3
Income tax $B	0.3	0.3	0.2	0.3	0.6	0.5	0.2	0.2	0.2	0.4	0.4	0.3	0.5	0.4	0.4	0.4	0.5	0.4	0.4
Net income $B	1.0	0.9	0.9	0.9	2.0	1.4	0.9	0.7	0.8	0.6	0.7	0.6	0.8	0.6	0.5	0.7	0.7	0.6	0.3
Free cash flow $B	1.4	0.9	0.9	1.3	1.8	1.6	0.8	0.8	0.9	0.8	0.6	0.6	0.4	1.0	0.7	0.9	0.8	0.9	0.7
EPS, diluted $	8.75	7.69	7.49	7.97	15.55	10.47	6.28	5.29	5.50	4.51	4.87	3.81	5.54	3.46	2.92	4.05	3.87	2.96	1.74
Dividend / sh $	·	·	·	·	·	·	·	·	1.80	1.65	1.52	1.32	1.20	0.81	0.47	0.40	0.40	0.40	0.40
Payout %	36	38	37	32	15	21	33	36	32	35	30	34	22	19	14	10	10	13	23
ROE %	14.2	13.3	14.0	15.3	30.2	23.1	15.8	14.5	16.2	13.9	15.8	13.5	20.9	14.2	12.2	18.0	19.2	16.1	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Quest Diagnostics Inc.vsHCA Healthcare, Inc.Same industry: Services-Medical Laboratories Quest Diagnostics Inc.vsTenet Healthcare Corp.Same industry: Services-Medical Laboratories Quest Diagnostics Inc.vsUniversal Health Services Inc.Same industry: Services-Medical Laboratories Quest Diagnostics Inc.vsFresenius Medical Care AGSame industry: Services-Medical Laboratories Quest Diagnostics Inc.vsLabcorp Holdings Inc.Same industry: Services-Medical Laboratories Quest Diagnostics Inc.vsDavita Inc.Same industry: Services-Medical Laboratories Quest Diagnostics Inc.vsBrightSpring Health Services, Inc.Same industry: Services-Medical Laboratories

Provenance

Company facts, as filed

How we verify · 0 failures in 85 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 3 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityServices-Medical Laboratories

Listed onNYSE

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2007